Drostanolone (Masteron)

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Drostanolone (Masteron)

An anabolic steroid approved for palliative treatment of advanced breast cancer in postmenopausal women.

Evidence category: Regulator / guideline. This describes the source category, not approval or certainty.

Regulatory statement in source: FDA-approved.

Drostanolone (Masteron) is an anabolic steroid derived from dihydrotestosterone. It was approved by the FDA for palliative treatment of advanced metastatic breast cancer in postmenopausal women, where it inhibited cancer growth. However, it is rarely used today due to other available options.

Benefits reported in the imported source

• Palliative treatment of advanced metastatic breast cancer in postmenopausal women.

Risks and limits

• Androgenic side effects
• Virilization in women
• Liver toxicity
• Lipid abnormalities

Source bottom line: Regulatory approval for advanced breast cancer, but now rarely used due to superior alternative treatments.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

No study protocol recorded in this snapshot. This does not establish that no study exists.

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

No community description recorded. This entry has no final B-82 outcome record; it is not a researched-empty finding.

Pharmacokinetic context

Historical half-life estimate: 48 hours. Llewellyn, Anabolics (Molecular Nutrition LLC, 2011), p.517 — compiled pharmacology reference; historically used clinically as Drolban/Masteril, no modern dedicated PK trial Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• Drugs@FDA: Drolban (drostanolone) NDA 012936
• Drostanolone - Wikipedia
• Drostanolone Propionate - DrugBank (availability check 2026-10-15: source not retrieved; HTTP 403)